OASIS SOLID-PHASE EXTRACTION PRODUCTS
[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
Simplifying
Solid-Phase Extraction
2
* U.S. patents 5,882,521 (1996), 5,976,376 (1998), 6,106,721 (1999), 6,254,780 (2001), 6,322,695 (2001),
6,468,422 (2002), 6,726,842 (2004), 6,773,583 (2004), 6,723,236 (2004)
Through the combination of innovative sorbent technology and hardware design,
Oasis® Products have become the first choice in solid-phase extraction (SPE).
Oasis Products are trusted by separation scientists across the globe to meet a wide
variety of sample preparation needs, ranging from a simple and fast matrix cleanup to
the need to solve the most difficult and highly selective sample preparation challenges.
Researchers rely on the superior technical performance of Oasis Products to achieve
unmatched purity, consistency, and quality in their sample preparation methods.
3
[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
¡
Fastest and simplest methods leading to the cleanest samples
¡
Highest sensitivity for small molecules and therapeutic peptides
¡
Reduced matrix effects for LC-MS/MS analyses
¡
Unsurpassed selectivity
¡
Highest SPE recovery
¡
Exceptional product quality and reproducibility
¡
Wide selection of sorbents
¡
Broad array of formats
4
Oasis HLB
Simplifying Solid-Phase Extraction
Waters introduced Oasis HLB in 1996, effectively changing
the way scientists performed solid-phase extraction (SPE), as
well as their expectations of this process. Constructed with a
water-wettable copolymer that is stable from pH 0–14, Oasis
HLB created a whole new range of solid-phase extraction
method development possibilities. It is the gold standard in
reversed-phase SPE, trusted by scientists across the world.
Traditional 5-step SPE protocol vs. the new 3-step SPE protocol with an Oasis HLB µElution Plate. (Typical loading range between
10–375 µL undiluted plasma.)
Hydrophilic-Lipophilic Balanced Copolymer
Hydrophilic monomer
Retention of polars
Lipophilic monomer
Reversed-phase retention
Traditionally, solid-phase extraction methods have required condition and equilibration steps to prepare the sorbent for
sample introduction. The condition step was required to wet the sorbent and allow liquid to enter the pores, enabling
retention within the sorbent. Once wetted, the sorbent needed to be equilibrated with aqueous solution to prepare it
for aqueous sample loading. Since Oasis HLB is a water-wettable sorbent, the analytes can interact with the sorbent
and are retained when loaded directly onto the sorbent in an aqueous sample solution. This eliminates the condition
and equilibration steps from the traditional solid-phase extraction protocol and reduces the number of processing
steps from 5 to 3. The result is an average reduction in solvent consumption of up to 70% and a 40% savings in sample
preparation time.
Save Time and Solvent by Moving from a 5-Step Protocol to a 3-Step Protocol
200 µL methanol (MeOH)
200 µL H2O
200 µL spiked dilute plasma
(100 µL plasma + 100 µL 4% H3PO4)
200 µL 5% MeOH in H2O
25 µL * 2 MeOH
200 µL spiked dilute plasma
(100 µL plasma + 100 µL 4% H3PO4)
200 µL 5% MeOH in H2O
25 µL * 2 MeOH
Elute
Standard (5-Step)
Simplified (3-Step)
Wash
Load
Equilibrate
Condition
5
[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
The ability to simplify and shorten SPE protocols is due to the unique water-wettable, balanced nature of the
hydrophilic/lipophilic Oasis Sorbent. Silica-based sorbents and other “Oasis-like” polymeric sorbents that are
not as water-wettable as Oasis HLB sacrifice performance when eliminating these condition and equilibration
steps. The chart below illustrates the difference that a thoroughly water-wettable sorbent such as Oasis HLB
can make in the implementation of this simplified, 3-step protocol. Oasis HLB is able to effectively retain a wide
range of compounds without the condition and equilibration steps. The competitors’ polymeric sorbent and a silica
based sorbent do not work in the absence of these steps.
Simplify Solid-Phase Extraction Without Sacrificing Recovery
The percent recoveries for a diverse set of compounds remain high with Oasis HLB when the condition and equilibration steps are
eliminated from the solid-phase extraction protocol. Under these same conditions, the silica based sorbent produces recoveries of
less than 10 percent for all analytes. The polymeric based sorbent produces recoveries of less than 10% for 7 compounds and less
than 20% and 50% for the other two compounds.
Additional information can be found within these application notes:
Application note
Literature code
A Simplified, Mixed-Mode Sample Preparation Strategy for Urinary Forensic Toxicology
Screening by UPLC-MS/MS
720005290EN
A Simplified, Solid-Phase Extraction (SPE) Protocol for Bioanalysis Using Oasis HLB
720005140EN
Search by literature code at waters.com
HLB μElution plate
Polymer-based μ plate
tC18 μElution plate
100
90
80
70
60
50
40
30
20
10
0
Azidothymidine (AZT)
Propranolo
l
7-Hydroxycoumarin
Phenacetin Protriptylin
e
Amitriptylin
e
Betamethasone
Alprazola
m
Naproxe
n
6
Oasis PRiME HLB
Oasis PRiME HLB is the first-of-its-kind SPE sorbent that sets the new performance standard for routine analyses.
The unique, patent-pending Oasis PRiME HLB Sorbent provides cleaner samples in less time and with less effort.
These powerful and easy-to-use benefits are important since solid-phase extraction provides many benefits
when performed prior to chromatographic analyses, especially when using mass detection.
These benefits include a reduction in matrix effects and chromatographic complexity as
well as the ability to increase sample concentration. However, scientists also desire
sample preparation methods that are SIMPLE to follow while providing
CLEANER sample eluates in the FASTEST time possible. Based on Oasis
HLB Technology, Oasis PRiME HLB was developed to meet these
needs with a focus on these advantages:
¡
Simpler
¡
Faster
¡
Even Cleaner
7
[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
Simpler
Easy, efficient protocols
Oasis PRiME HLB was created to have the same powerful benefits made
possible with Oasis HLB. The Oasis PRiME HLB Copolymer is extremely
water-wettable, making it possible to eliminate the condition and equilibration
steps that are required when using silica-based or other polymeric sorbents.
Without these additional steps, sorbents that are not as water-wettable are
unable to effectively retain analytes of interest during the sample load step,
causing a loss of recovery. The ability to skip these steps saves valuable
sample processing time and costly solvent purchase and disposal.
Oasis PRiME HLB allows you to choose the sample preparation method
that meets your analytical needs. The simplicity of the sorbent design and
protocols makes it easy to implement into your laboratory's workflow without
requiring solid-phase extraction expertise.
Load pre-treated sample
Wash: 5% MeOH
Elute: 90/10 acetonitrile/MeOH
Load pre-treated sample
Analytes pass-through unretained
Rinse to collect hold up volume
(optional)
Use the 2-step solid-phase
extraction protocol to remove
matrix interferences quickly if
your sample solution contains
a high concentration of organic
solvent(s) and concentration and/
or salt removal is not required.
This protocol is perfectly suited
for multiple residue screening of
veterinary drugs, pesticides and
mycotoxins in various food samples.
Use the 3-step solid-phase
extraction protocol to remove the
most matrix interferences, including
salts, phospholipids, and proteins.
This technique also allows for
sample concentration/enrichment.
It is the perfect solution for routine
bioanalytical sample clean up or any
other reversed-phase solid-phase
extraction application.
3-step protocol (catch and release SPE)
2-step protocol (pass-through SPE)
8
Faster
Faster, more even flows across cartridges and plates with less plugging
Oasis PRiME HLB has been designed to increase speed both within the SPE device itself and in your laboratory’s
sample processing workflow. Not only can you eliminate the condition and equilibration steps, viscous samples flow
more easily through the cartridges and 96-well plates due to a new, optimized frit and sorbent design. Flow rates
through the devices are much faster for common matrices such as plasma, urine, and milk. The optimal load, wash,
and elution flow rates are achieved using less vacuum or positive pressure than with other SPE devices.
Increased Sample Processing Speed with Oasis PRiME HLB
Matrix
Device Format
Oasis PRiME HLB Speed
Increase
1:1 Diluted Plasma
µElution Plate
2–3x Faster
1:1 Diluted Plasma
1 cc/30 mg Cartridge
4x Faster
1:1 Diluted Urine
30 mg Plate
6x Faster
1:1 Diluted Urine
10 mg Plate
2x Faster
1:1 Diluted Milk
3 cc/60 mg Cartridge
1–2x Faster
1:1 Diluted Milk
6 cc/200 mg Cartridge
2–3x Faster
Flow comparison vs. another reversed-phase SPE sorbent. Loading performed with 4 inch Hg (n=4).
Faster processing time compared to other sample preparation techniques
With the elimination of the condition and equilibration steps, Oasis PRiME HLB provides faster processing time
compared to other sample preparation techniques such as solid-supported liquid extraction (SSLE). Scientists can
achieve highly reproducible sample clean up with less process complexity and fewer steps.
Reduce Sample Preparation Time and Steps with Oasis PRiME HLB Compared to SSLE
Oasis PRiME HLB reduces sample preparation
time and complexity by providing efficient sample
preparation. Compared to SSLE, samples can be
processed in fewer steps and less time.
SSLE
1.
Add sample (3 min)
2.
Wait (5–10 min)
3.
Add extraction solvent (2 min)
4.
Wait (5–10 min)
5.
Extract (1 min)
6.
Evaporate (5 min)
7.
Reconstitute (2 min)
TOTAL
PROCESS-
ING TIME:
28–33min.
Oasis PRiME HLB
1.
Load pre-treated sample (4 min)
2.
Wash: 5% MeOH (3.5 min)
3.
Elute: 90/10 acetonitrile/MeOH (2 min)
TOTAL
PROCESS-
ING TIME:
9.5min.
9
[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
Even Cleaner
Oasis PRiME HLB removes more than 95% of common matrix interferences such as proteins, salts, and phospholipids,
using the generic protocol without any additional optimization. Cleaner samples means less variability in your
analytical results from sample to sample, increasing the robustness of your analyses.
Food analysis can provide an exceptional challenge in sample preparation. Meat and milk samples are typically extracted
with an acetonitrile based solvent for LC-MS determination of veterinary drug residues. Among the most significant
co-extractable substances are fats and polar lipids, particularly phospholipids. For example, 1 mL of whole milk contains
about 35 mg of fat and about 0.3 mg of phospholipids. A gram of pork muscle typically contains about 100 mg of fat and
about 5 mg of phospholipids. Reversed-phase sorbents such as C18 are effective for removal of fat from the acetonitrile
based extraction solvent, but are ineffective for removal of phospholipids. Excessive amounts of phospholipids can
shorten LC column life and contribute to ion-suppression and contamination in the mass spectrometer. Oasis PRiME
HLB is highly effective for removal of both phospholipids and fats from meat and milk extracts.
Fewer phospholipids remain in the final sample eluate with the Oasis PRiME HLB Sorbent and 3-step protocol, compared to the final
eluates using traditional 5-step protocol on the competitors' sorbents. This removal is also more reproducible with Oasis PRiME HLB
as indicated by the error bars (n=5).
Phospholipids Remaining in Final Eluate
Oasis PRiME HLB
Competitor SX
Competitor SO
PPT 1:3
Plasma:ACN
0
7000000
6000000
5000000
4000000
3000000
2000000
1000000
Phospholipids Remaining in Final Eluate
%
0
1: MRM of 12 Channels ES+
TIC (Phospholipid)
1.87e8
4.58
4.33
Silica C18
100
1
2
3
4
5
6 min
1
2
3
4
5
6 min
%
0
1: MRM of 12 Channels ES+
TIC (Phospholipid)
1.87e8
4.33
Oasis PRiME HLB
100
Phospholipids Remaining After Pass-through Sample Clean Up
Lipid removal from acetonitrile-based meat extract results: Oasis PRiME HLB removes more than 90% of hexane-extractable total
lipids (determined gravimetrically). Oasis PRiME HLB successfully removes both phospholipids and fats in pass-through method.
The silica C18 sorbent removes only fats, NOT phospholipids. Removal of both of these components results in fewer matrix effects
and less column and/or instrument contamination.
10
Reduced Matrix Effects
The presence of matrix interferences in a sample
limits the maximum sensitivity that can be achieved.
In addition, the removal of matrix interferences
increases the robustness and reproducibility of
your analytical results.
Analyte
% RSD of Matrix Factors
Amitriptyline
6.03
Nortriptyline
5.53
Imipramine
8.36
Desipramin
e
7.15
Doxepin
5.96
Following extraction with an Oasis Mixed-Mode Sorbent, the
matrix effects were evaluated for a panel of 5 antidepressant
drugs in multiple lots of urine. The RSD of the matrix factors was
determined to be between 5.5 and 8.4%, which is well within
the 15% limit required by regulatory agencies.
Sorbents
The Mixed-Mode Ion Exchange/Reversed-Phase Sorbents are all based on the Oasis HLB Copolymer to provide a
range of options for method development.
Oasis WCX
Mixed-Mode Weak Cation eXchange sorbent for
strong bases and quaternary amines
Oasis MCX
Mixed-Mode Cation eXchange sorbent for bases
Oasis MAX
Mixed-Mode Anion eXchange sorbent for acids
Oasis WAX
Mixed-Mode Weak Anion eXchange
sorbent for strong acids
Oasis HLB
Hydrophilic-Lipophilic Balanced reversed-phase
sorbent for acids, bases, and neutrals
pKa <1
pKa~5
pKa >18
pKa ~6 and ~9
Hydrophilic
Retention
of Polars
Lipophilic
RP Retention
Stable from pH 0–14
Water-wettable
No silanol interactions
11
[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
Sensitivity
The Oasis Mixed-Mode Sorbents, which are all
built upon the unique water-wettable Oasis HLB
Copolymer, provide both reversed-phase and ion
exchange modes of retention, enabling greater
cleanup selectivity and sensitivity for both acidic
and/or basic compounds. An example of this
outstanding capability can be seen with the Oasis
µElution Plate. This product employs a patented
design to concentrate a sample up to 15x without
requiring evaporation or reconstitution.
LOQ of Alprazolam from Plasma
A. Matrix blank
%
0
100
1.54
1.58
1.62
1.66
1.70
1.74
1.78 min
B. 1 pg/mL
spiked sample
%
0
100
1.54
1.58
1.62
1.66
1.70
1.74
1.78 min
1.61
1.52
1.55
1.66
1.73
0
A. Matrix blank
%
100
0.50
1.00
1.50
2.00 min
0
1.04
138
Baseline
x5
B. 1 pg/mL
spiked sample
%
100
0.50
1.00
1.50
2.00 min
%
0
1.04
765
Baseline
x25
C. 5 pg/mL
spiked sample
100
0.50
1.00
1.50
2.00 min
LC-MS/MS chromatogram of 1 pg/mL of alprazolam from rat plasma.
Selectivity
Having a variety of tools for method
development allows separation
scientists to optimize their protocols
to achieve maximum selectivity
and sensitivity. Small molecules
and therapeutic peptides require
different approaches to sample
preparation due to their solubilities
and stabilities. Oasis SPE Products
are available in a variety of sorbents
and can be used in conjunction with
a simple, logical approach to quickly
develop new separation methods.
* When using the µElution plate, perform the second elution using 5% NH4OH in 60:40
CH3CN:CH3OH (for protocol 1) and 2% HCOOH in 60:40 CH3CN:CH3OH (for protocol 2).
Oasis 2 X 4 Method Development Protocol
Load
Pre-treated sample
Wash 1
2% Formic acid
Wash 2 or Elute 1
100% MeOH
Elute 2
5% NH4OH in MeOH
4-Step Protocol
Load
Pre-treated sample
Wash
5% NH4OH
Elute 2
2% Formic Acid in MeOH
Elute
100% MeOH
4-Step Protocol
Bases
Strong Acids
Strong Bases
Acids
pKa 2–10
OASIS MCX
Bases
pKa <1.0
OASIS WAX
Strong Acids
pKa >10
OASIS WCX
Strong Bases
pKa 2–8
OASIS MAX
Acids
NEUTRALS
NEUTRALS
12
A. Matrix blank
%
0
100
1.54
1.58
1.62
1.66
1.70
1.74
1.78 min
B. 1 pg/mL
spiked sample
%
0
100
1.54
1.58
1.62
1.66
1.70
1.74
1.78 min
1.61
1.52
1.55
1.66
1.73
0
A. Matrix blank
%
100
0.50
1.00
1.50
2.00 min
0
1.04
138
Baseline
x5
B. 1 pg/mL
spiked sample
%
100
0.50
1.00
1.50
2.00 min
%
0
1.04
765
Baseline
x25
C. 5 pg/mL
spiked sample
100
0.50
1.00
1.50
2.00 min
Peptides
The increasing number of peptide based therapeutics brings new challenges
to the typical bioanalytical laboratory. Sensitive, selective, and robust
bioanalytical methods, which would ideally meet current regulatory criteria,
must be developed for these types of compounds, which differ significantly
from small molecule drugs.
Because of their size and charge state distribution, sensitivity by mass
spectrometry may be lower for biomolecules than typical small molecules,
necessitating sample concentration and other means of increasing
overall method sensitivity. We provide basic starting protocols for sample
preparation and show how the use of mixed-mode ion-exchange solid-phase
extraction in µElution format can simplify the process of method development
for peptide therapeutics and biomarkers.
Oasis µElution Plate technology for peptides enables:
■
Up to 15x concentration without evaporation
■
Concentration is often necessary to reach the limit of detection (LOD)
with peptides
■
Helps minimize analyte loss
■
Eliminates problems re-solubilizing peptides after dry-down steps
■
Beneficial for thermally unstable peptides
Oasis WCX
µElution
Oasis MAX
µElution
Dilute plasma with
4% H3PO4
Condition MeOH/
Equilibrate H20
Wash 1: 5% NH4OH
Wash 2: 20% ACN
Elute: 1% TFA in
75/25 ACN/H2O
PROTOCOL
Dilute: H2O
A. Matrix blank
%
0
100
1.54
1.58
1.62
1.66
1.70
1.74
1.78 min
B. 1 pg/mL
spiked sample
%
0
100
1.54
1.58
1.62
1.66
1.70
1.74
1.78 min
1.61
1.52
1.55
1.66
1.73
0
A. Matrix blank
%
100
0.50
1.00
1.50
2.00 min
0
1.04
138
Baseline
x5
B. 1 pg/mL
spiked sample
%
100
0.50
1.00
1.50
2.00 min
%
0
1.04
765
Baseline
x25
C. 5 pg/mL
spiked sample
100
0.50
1.00
1.50
2.00 min
A. Matrix blank
%
0
100
1.54
1.58
1.62
1.66
1.70
1.74
1.78 min
B. 1 pg/mL
spiked sample
%
0
100
1.54
1.58
1.62
1.66
1.70
1.74
1.78 min
1.61
1.52
1.55
1.66
1.73
0
A. Matrix blank
%
100
0.50
1.00
1.50
2.00 min
0
1.04
138
Baseline
x5
B. 1 pg/mL
spiked sample
%
100
0.50
1.00
1.50
2.00 min
%
0
1.04
765
Baseline
x25
C. 5 pg/mL
spiked sample
100
0.50
1.00
1.50
2.00 min
LOD and LOQ of Desmopressin from Plasma
LC-MS/MS chromatogram of 1 pg/mL and 5 pg/mL of desmopressin from human plasma.
13
[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
Formats
¡
Ultra-clean syringe barrel and frits.
¡
Available with cartridges ranging from 1 cc to 60 cc.
¡
Flangeless syringe-barrel cartridges available in 1 cc, 3 cc, and 6 cc configurations.
¡
Plus-style cartridges with Luer inlet hub and outlet tip with 225 mg of sorbent.
Sy
rin
ge
-B
ar
re
l
C
ar
tr
idge
s
¡
Ultra-clean glass syringe with Teflon® frit.
¡
For trace level detection and analysis at part-per-trillion levels.
¡
Available in 5 cc with 200 mg of sorbent configuration.
G
las
s
C
ar
tr
idge
s
¡
For rugged, reproducible, and ultra-fast on-line analysis.
¡
Wide choice of configurations, particle sizes, and sorbent chemistries.
¡
Available with six patented Oasis Sorbents—HLB, PRiME HLB, MCX, MAX, WCX, and WAX.
¡
High recovery and reproducible results for a wide range of compounds.
¡
Cartridge format for use with Spark Holland Prospekt-2™/Symbiosis™
systems also available.
O
n-
Li
ne C
ol
um
ns
an
d C
ar
tr
idge
s
¡
Innovative, award-winning two-stage well design.
¡
High throughput and high recovery.
¡
Available with 5 mg, 10 mg, 30 mg, and 60 mg of sorbent per well.
¡
Compatible with most liquid-handling robotic systems for automated, reliable
high throughput SPE (HT-SPE).
96
-we
l
Ex
tr
ac
tion
P
la
te
s
¡
Patented μElution plate design.
¡
Ideal for SPE cleanup and analyte enrichment of sample volumes ranging from 10 µL to 375 µL.
¡
No evaporation and reconstitution necessary due to elution volumes as low as 25 µL.
¡
Up to a 15x increase in concentration.
¡
Compatible with most liquid-handling robotic systems for automated, reliable high
throughput SPE (HT-SPE).
µE
lut
ion
Pl
at
es
Quality
Waters expert manufacturing capabilities and stringent quality controls have established the highest standard in
batch-to-batch and lot-to-lot reproducibility for SPE sorbents, enabling scientists to develop robust, accurate, and
precise analytical methods. Scientists can be confident that the methods can be seamlessly transferred to laboratories
across the globe.
\HDUV
Reco
ve
ry
%
No Batch Reservations Needed: Consistently high recoveries over more than 15 years of production.
RSDs of recovery for:
Procainamide: 1.90%
Ranitidine: 1.68%
Acetaminophen: 1.65%
14
Oasis HLB Solid-Phase Extraction Products
Description
Format
Particle Size
Qty.
Part No.
Oasis HLB Cartridge
1 cc/10 mg
30 µm
100/box
186000383
Oasis HLB Cartridge
1 cc/30 mg
30 µm
100/box
WAT094225
Oasis HLB Cartridge
1 cc/30 mg
30 µm
1,000/box 186003908
Oasis HLB Flangeless Cartridge
1 cc/30 mg
30 µm
100/box
186001879
Oasis HLB Cartridge with Gilson
ASPEC adapter
1 cc/10 mg
30 µm
500/box
186000988
Oasis HLB Cartridge with Gilson
ASPEC adapter
1 cc/30 mg
30 µm
500/box
WAT058882
Oasis HLB Cartridge
3 cc/60 mg
30 µm
100/box
WAT094226
Oasis HLB Cartridge
3 cc/60 mg
30 µm
1,000/box
186007646
Oasis HLB Flangeless Cartridge
3 cc/60 mg
30 µm
100/box
186001880
Oasis HLB Cartridge with Gilson
ASPEC adapter
3 cc/60 mg
30 µm
500/box
WAT058883
Oasis HLB Cartridge
6 cc/200 mg
30 µm
30/box
WAT106202
Oasis HLB Cartridge
3 cc/400 mg
60 µm
100/box
186003849
Oasis HLB Cartridge
3 cc/540 mg
60 µm
100/box
186004134
Oasis HLB Flangeless Cartridge
3 cc/540 mg
60 µm
100/box
186003852
Oasis HLB Cartridge
6 cc/150 mg
30 µm
30/box
186003365
Oasis HLB Cartridge
6 cc/150 mg
60 µm
30/box
186003379
Oasis HLB Cartridge
6 cc/500 mg
60 µm
30/box
186000115
Oasis HLB Cartridge
12 cc/500 mg
60 µm
20/box
186000116
Oasis HLB Cartridge
20 cc/1 g
60 µm
20/box
186000117
Oasis HLB Cartridge
35 cc/6 g
60 µm
10/box
186000118
Oasis HLB Plus Short Cartridge
225 mg
60 µm
50/box
186000132
Oasis HLB Plus Light Cartridge
30 mg
30 µm
50/box
186005125
Oasis HLB Vac RC Cartridge
20 cc/30 mg
30 µm
50/box
186000382
Oasis HLB Vac RC Cartridge
20 cc/60 mg
30 µm
50/box
186000381
Oasis HLB Glass Cartridge
5 cc/200 mg
60 µm
30/box
186000683
Oasis HLB µElution Plate
2 mg/96-well
30 µm
1/pk
186001828BA
Oasis HLB Plate
5 mg/96-well
30 µm
1/pk
186000309
Oasis HLB Plate
10 mg/96-well
30 µm
1/pk
186000128
Oasis HLB Plate
30 mg/96-well
30 µm
1/pk
WAT058951
Oasis HLB Plate
60 mg/96-well
60 µm
1/pk
186000679
Oasis MCX Solid-Phase Extraction Products (Cation Exchange)
Description
Format
Particle Size
Qty.
Part No.
Oasis MCX Cartridge
1 cc/10 mg
30 µm
100/box
186004648
Oasis MCX Cartridge
1 cc/30 mg
30 µm
100/box
186000252
Oasis MCX Flangeless Cartridge
1 cc/30 mg
30 µm
100/box
186001881
Oasis MCX Cartridge
1 cc/30 mg
60 µm
100/box
186000782
Oasis MCX Cartridge
3 cc/60 mg
30 µm
100/box
186000254
Oasis MCX Flangeless Cartridge
3 cc/60 mg
30 µm
100/box
186001882
Oasis MCX Cartridge
3 cc/60 mg
60 µm
100/box
186000253
Oasis MCX Cartridge
6 cc/150 mg
30 µm
30/box
186000256
Oasis MCX Cartridge
6 cc/150 mg
60 µm
30/box
186000255
Oasis MCX Cartridge
6 cc/500 mg
60 µm
30/box
186000776
Oasis MCX Cartridge
20 cc/1 g
60 µm
20/box
186000777
Oasis MCX Cartridge
35 cc/6 g
60 µm
10/box
186000778
Oasis MCX Plus Short Cartridge
225 mg
60 µm
50/box
186003516
Oasis MCX Vac RC Cartridge
20 cc/60 mg
30 µm
50/box
186000261
Oasis MCX Vac RC Cartridge
20 cc/60 mg
60 µm
50/box
186000380
Oasis MCX µElution Plate
2 mg/96-well
30 µm
1/pk
186001830BA
Oasis MCX Plate
10 mg/96-well
30 µm
1/pk
186000259
Oasis MCX Plate
30 mg/96-well
30 µm
1/pk
186000248
Oasis MCX Plate
30 mg/96-well
60 µm
1/pk
186000250
Oasis MCX Plate
60 mg/96-well
60 µm
1/pk
186000678
Oasis MAX Solid-Phase Extraction Products (Anion Exchange)
Description
Format
Particle Size
Qty.
Part No.
Oasis MAX Cartridge
1 cc/10 mg
30 µm
100/box
186004649
Oasis MAX Cartridge
1 cc/30 mg
30 µm
100/box
186000366
Oasis MAX Flangeless Cartridge 1 cc/30 mg
30 µm
100/box
186001883
Oasis MAX Cartridge
3 cc/60 mg
30 µm
100/box
186000367
Oasis MAX Cartridge
3 cc/60 mg
60 µm
100/box
186000368
Oasis MAX Flangeless Cartridge
3 cc/60 mg
30 µm
100/box
186001884
Oasis MAX Cartridge
6 cc/150 mg
30 µm
30/box
186000369
Oasis MAX Cartridge
6 cc/150 mg
60 µm
30/box
186000370
Oasis MAX Cartridge
6 cc/500 mg
60 µm
30/box
186000865
Oasis MAX Plus Short Cartridge
225 mg
60 µm
50/box
186003517
Oasis MAX Vac RC Cartridge
20 cc/30 mg
30 µm
50/box
186000372
Oasis MAX Vac RC Cartridge
20 cc/60 mg
30 µm
50/box
186000371
Oasis MAX Vac RC Cartridge
20 cc/60 mg
60 µm
50/box
186000378
Oasis WCX Solid-Phase Extraction Products (Weak Cation Exchange)
Description
Format
Particle Size
Qty.
Part No.
Oasis WCX Cartridge
1 cc/10 mg
30 µm
100/box
186004650
Oasis WCX Cartridge
1 cc/30 mg
30 µm
100/box 186002494
Oasis WCX Cartridge
3 cc/60 mg
30 µm
100/box
186002495
Oasis WCX Cartridge
6 cc/150 mg
30 µm
30/box
186002498
Oasis WCX Cartridge
1 cc/30 mg
60 µm
100/box
186002496
Oasis WCX Cartridge
3 cc/60 mg
60 µm
100/box
186002497
Oasis WCX Cartridge
6 cc/500 mg
60 µm
30/box
186004646
Oasis WCX Plus Short Cartridge
225 mg
60 µm
50/box
186003518
Oasis WCX µElution Plate
2 mg/96-well
30 µm
1/pk
186002499
Oasis WCX 96-well Plate
10 mg/96-well
30 µm
1/pk
186002501
Oasis WCX 96-well Plate
30 mg/96-well
30 µm
1/pk
186002503
Oasis WAX Solid-Phase Extraction Products (Weak Anion Exchange)
Description
Format
Particle Size
Qty.
Part No.
Oasis WAX Cartridge
1 cc/10 mg
30 µm
100/box
186004651
Oasis WAX Cartridge
1 cc/30 mg
30 µm
100/box 186002489
Oasis WAX Cartridge
3 cc/60 mg
30 µm
100/box
186002490
Oasis WAX Cartridge
6 cc/150 mg
30 µm
30/box
186002493
Oasis WAX Cartridge
1 cc/30 mg
60 µm
100/box
186002491
Oasis WAX Cartridge
3 cc/60 mg
60 µm
100/box
186002492
Oasis WAX Cartridge
6 cc/500 mg
60 µm
30/box
186004647
Oasis WAX Plus Cartridge
225 mg
60 µm
50/box
186003519
Oasis WAX µElution Plate
2 mg/96-well
30 µm
1/pk
186002500
Oasis WAX 96-well Plate
10 mg/96-well
30 µm
1/pk
186002502
Oasis WAX 96-well Plate
30 mg/96-well
30 µm
1/pk
186002504
Oasis WAX 96-well Plate
60 mg
30 µm
1/pk
186003915
Oasis PRiME HLB Solid-Phase Extraction Products
Description
Format
Qty.
Part No.
Oasis PRiME HLB µElution Plate
3 mg
1/pk
186008052
Oasis PRiME HLB 96-well Plate
10 mg
1/pk
186008053
Oasis PRiME HLB 96-well Plate
30 mg
1/pk
186008054
Oasis PRiME HLB Cartridge
1 cc/30 mg
100/box
186008055
Oasis PRiME HLB Cartridge
3 cc/60 mg
100/box
186008056
Oasis PRiME HLB Cartridge
3 cc/150 mg
100/box
186008717
Oasis PRiME HLB Cartridge
6 cc/200 mg
30/box
186008057
Oasis PRiME HLB Cartridge
6 cc/500 mg
30/box
186008718
Oasis PRiME HLB Plus Light Cartridge
Plus Light/100 mg
50/box
186008886
Oasis PRiME HLB Plus Short Cartridge
Plus Light/335 mg
50/box
186008887
Oasis MAX Solid-Phase Extraction Products (Anion Exchange) Continued
Description
Format
Particle Size
Qty.
Part No.
Oasis MAX µElution Plate
2 mg/96-well
30 µm
1/pk
186001829
Oasis MAX Plate
10 mg/96-well
30 µm
1/pk
186000375
Oasis MAX Plate
30 mg/96-well
30 µm
1/pk
186000373
Oasis MAX Plate
60 mg/96-well
30 µm
1/pk
186001256
Oasis MAX Plate
60 mg/96-well
60 µm
1/pk
186001205
15
[ OASIS SOLID-PHASE EXTRACTION PRODUCTS ]
Therapeutic Peptide Method Development Kits
Description
Part No.
UPLC® Therapeutic Peptide Method Development Kit Includes:
1 Oasis Peptide Method Development 96-well µElution Plate,
(part no.: 186004713)
1 ACQUITY UPLC® Peptide BEH C18, 300Å, 1.7 µm, 2.1 x 50 mm Column, (part
no.: 186003685)
3 96-well 1 mL Collection Plate and Cap Mat, (part no.: 600001043)
176001835
HPLC Therapeutic Peptide Method Development Kit Includes:
1 Oasis Peptide Method Development 96-well µElution Plate,
(part no.: 186004713)
1 XBridge® Peptide BEH C18, 300Å, 3.5 µm, 2.1 x 50 mm Column,
(part no.: 186003607)
3 96-well 1 mL Collection Plate and Cap Mat, (part no.: 600001043)
176001836
Oasis Method Development Kits
Description
Format
Particle Size Part No.
Oasis Sorbent Selection Plate, 3 rows each:
MCX, MAX, WCX, and WAX
10 mg/96-well
30 µm
186003249
Oasis µElution Sorbent Selection Plate,
3 rows each: MCX, MAX, WCX, and WAX
2 mg/96-well
30 µm
186004475
Oasis Sorbent Selection Cartridge Kit,
10 each: MCX, MAX, WCX, and WAX
1 cc/30 mg
30 µm
186003463
Oasis Sorbent Selection Flangeless Cartridge
Kit, 10 each: MCX, MAX, WCX, and WAX
1 cc/10 mg
30 µm
186006344
Oasis Sorbent Selection Flangeless Cartridge
Kit, 10 each: MCX, MAX, WCX, and WAX
1 cc/30 mg
30 µm
186006345
Oasis µElution 96-well Plates
Description
Particle Size
Qty.
Part No.
Oasis PRiME HLB
—
1/pk
186008052
Oasis HLB
30 µm
1/pk
186001828BA
Oasis MCX
30 µm
1/pk
186001830BA
Oasis MAX
30 µm
1/pk
186001829
Oasis WCX
30 µm
1/pk
186002499
Oasis WAX
30 µm
1/pk
186002500
Oasis 96-well Plates
Particle
Size
5 mg/
96-well
10 mg/
96-well
30 mg/
96-well
60 mg/
96-well
Description
1/pk
1/pk
1/pk
1/pk
Oasis PRiME HLB
—
—
186008053
186008054
—
Oasis HLB
30 µm
186000309
186000128
WAT058951
—
Oasis HLB
60 µm
—
—
—
186000679
Oasis MCX
30 µm
—
186000259
186000248
—
Oasis MCX
60 µm
—
—
186000250
186000678
Oasis MAX
30 µm
—
186000375
186000373
186001256
Oasis MAX
60 µm
—
—
—
186001205
Oasis WCX
30 µm
—
186002501
186002503
—
Oasis WAX
30 µm
—
186002502
186002504
186003915
Oasis Symbiosis/Prospekt-2 Cartridges
Description
Format
Particle
Size
Qty.
Part No.
Oasis HLB Symbiosis/Prospekt-2 Cartridge
1 x 10 mm
30 µm 96/box 186005781
Oasis HLB Symbiosis/Prospekt-2 Cartridge
1 x 20 mm
30 µm 96/box 186005786
Oasis MCX Symbiosis/Prospekt-2 Cartridge
1 x 10 mm
30 µm 96/box 186005782
Oasis MCX Symbiosis/Prospekt-2 Cartridge 1 x 20 mm
30 µm 96/box 186004653
Oasis MAX Symbiosis/Prospekt-2 Cartridge
1 x 10 mm
30 µm 96/box 186005783
Oasis MAX Symbiosis/Prospekt-2 Cartridge 1 x 20 mm
30 µm 96/box 186004654
Oasis WCX Symbiosis/Prospekt-2 Cartridge 1 x 10 mm
30 µm 96/box 186005784
Oasis WCX Symbiosis/Prospekt-2 Cartridge 1 x 20 mm
30 µm 96/box 186004655
Oasis WAX Symbiosis/Prospekt-2 Cartridge
1 x 10 mm
30 µm 96/box 186005785
Oasis WAX Symbiosis/Prospekt-2 Cartridge 1 x 20 mm
30 µm 96/box 186004656
SPE Columns for Waters UPLC with On-Line SPE Technology
Description
Format
Particle
Size
Qty.
Part No.
Oasis HLB Direct Connect HP Column
2.1 x 30 mm
20 µm
1/pk
186005231
XBridge C18 Direct Connect HP Column
2.1 x 30 mm
10 µm
1/pk 186005232
XBridge C8 Direct Connect HP Column
2.1 x 30 mm
10 µm
1/pk 186005233
Oasis Bulk Material and Glass Cartridge
Description
Particle Size
Qty.
Part No.
Oasis HLB
30 µm/100 gm
—
186007549
Oasis HLB
30 µm/250 gm
—
186007550
Oasis MAX
30 µm/100 gm
—
186007551
Oasis MAX
30 µm/250 gm
—
186007552
Oasis MCX
30 µm/100 gm
—
186007553
Oasis MCX
30 µm/250 gm
—
186007554
Oasis HLB Glass Cartridge
60 µm
30/box
186000683
On-Line SPE Columns and Cartridge Columns
Description
Format
Particle Size
Qty.
Part No.
Oasis HLB Column
2.1 x 20 mm
5 µm
1/pk
186002034
Oasis HLB Column
3.0 x 20 mm
5 µm
1/pk
186002037
Oasis HLB Column
3.9 x 20 mm
5 µm
1/pk
186002040
Oasis HLB Cartridge Column
3.9 x 20 mm
5 µm
1/pk
186001413
Oasis HLB Column
4.6 x 20 mm
5 µm
1/pk
186002043
Oasis HLB Column
2.1 x 20 mm
15 µm
1/pk
186002035
Oasis HLB Column
3.0 x 20 mm
15 µm
1/pk
186002038
Oasis HLB Column
3.9 x 20 mm
15 µm
1/pk
186002041
On-Line SPE Columns and Cartridge Columns Continued
Description
Format
Particle Size
Qty.
Part No.
Oasis HLB Cartridge Column
3.9 x 20 mm
15 µm
1/pk
186001414
Oasis HLB Column
4.6 x 20 mm
15 µm
1/pk
186002044
Oasis HLB Column
2.1 x 20 mm
25 µm
1/pk
186002036
Oasis HLB Cartridge Column
2.1 x 20 mm
25 µm
1/pk
186000706
Oasis HLB Column
3.0 x 20 mm
25 µm
1/pk
186002039
Oasis HLB Column
3.9 x 20 mm
25 µm
1/pk
186002042
Oasis HLB Column
4.6 x 20 mm
25 µm
1/pk
186002045
Oasis HLB Direct Connect Column
2.0 x 15 mm
25 µm
1/pk
186001792
Oasis MCX Column
2.1 x 20 mm
30 µm
1/pk
186002046
Oasis MCX Cartridge Column
2.1 x 20 mm
30 µm
1/pk
186002051
Oasis MCX Column
3.0 x 20 mm
30 µm
1/pk
186002047
Oasis MCX Column
3.9 x 20 mm
30 µm
1/pk
186002048
Oasis MCX Column
4.6 x 20 mm
30 µm
1/pk
186002049
Oasis MAX Column
2.1 x 20 mm
30 µm
1/pk
186002052
Oasis MAX Cartridge Column
2.1 x 20 mm
30 µm
1/pk
186002057
Oasis MAX Column
3.0 x 20 mm
30 µm
1/pk
186002053
Oasis MAX Column
3.9 x 20 mm
30 µm
1/pk
186002054
Oasis MAX Column
4.6 x 20 mm
30 µm
1/pk
186002055
Oasis WCX Column
2.1 x 20 mm
30 µm
1/pk
186002505
Oasis WCX Column
3.9 x 20 mm
30 µm
1/pk
186002507
Oasis WAX Column
2.1 x 20 mm
30 µm
1/pk
186002508
Oasis WAX Column
3.9 x 20 mm
30 µm
1/pk
186002509
Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
www.waters.com
www.waters.com/oasis
Waters, The Science of What’s Possible, UPLC, ACQUITY UPLC, XBridge, and Oasis are registered
trademarks of Waters Corporation. Teflon is a registered trademark of E.I. du Pont de Nemours
and Company or its affiliates. Prospekt and Symbiosis are trademarks of Spark Holland. All other
trademarks are the property of their respective owners.
©2017 Waters Corporation. Printed in the U.S.A.
April 2020 720001692EN KP-SIG
For your local sales
office, please visit
waters.com/contact
Podobná PDF
Klíčová slova
Klíčová slova
Klíčová slova